Granata Bio brings deep expertise in business development, research and development (R&D), regulatory strategy and commercialization. As part of the transaction, Richter will become a major investor in Granata Bio and gain a seat on Granata Bio’s Board of Directors.

Granata Bio is renowned for its agile approach and innovative solutions in the biotechnology sector. The company boasts a balanced portfolio and a range of robust capabilities, including cutting-edge R&D, comprehensive business development strategies, navigating regulatory landscapes and long-term experience in commercializing fertility products on US market.

This partnership aligns perfectly with Richter's commitment to expanding its presence in the United States and enhancing its Women's Health Care (WHC) strategy. Granata Bio is an ideal partner to achieve this strategic goal, offering strong relationships with key opinion leaders and a track record of effective market access in the US.

The collaboration between the companies is further strengthened by the signing of a binding term sheet for the co-development for Bemfola – Richter’s recombinant follicle stimulating hormone (FSH) product – for the US market, and a royalty purchase agreement for Granata Bio’s human menopausal gonadotropin (hMG) in the US, securing future royalty stream income for Richter.

Péter Turek, Global Head of WHC Business Unit of Richter stated: "These transactions are testament to the execution of our corporate strategy and dedication to the US market. We are committed to bringing Richter assets to the US market, and we believe that our collaboration with Granata Bio will significantly support our ambitions in this important region. We are excited about this partnership advancing fertility treatments and making a meaningful positive impact for many people in the US." 

Fertility is a strategic therapeutic area for Richter. The US follitropine market is defined by sales exceeding EUR 2.3bn in 2024 and a compound annual growth rate (CAGR) of around 11% over the last 4 year. The partnership and the business development collaboration with Granata Bio presents a great opportunity to establish Richter’s presence in the US fertility market.

About Gedeon Richter Plc.

Richter aspires to be a global innovator in some key scientific fields, while dedicated to making medicines more accessible worldwide. Founded in 1901, headquartered in Hungary, with a market capitalization of EUR 4.7bn and sales of EUR 2.2bn in 2024, it operates Central Europe's largest R&D hub. Its research drives breakthroughs in Neuropsychiatry and Women's Healthcare, while Biotechnology and General Medicines strengthen its affordable treatment portfolio. Committed to sustainable growth, Richter invests in R&D, manufacturing excellence, and digitalization to advance medical innovation. Learn more at www.gedeonrichter.com

About Granata Bio

Granata Bio is a U.S.-based biopharmaceutical company committed to advancing innovation in women's health and infertility. Founded in 2018, the company's pipeline includes a range of fertility therapies, with collaborations spanning multiple drug classes to address unmet needs in reproductive medicine. Granata Bio is the parent company of Oviva Therapeutics, Inc., a wholly owned subsidiary developing first-in-class therapeutics aimed at preserving ovarian function and extending female health span. For more information, please visit www.granata.bio

For further information:

Investors:        Róbert Réthy, CFA                                                                +36 20 342 2555 

Media:               Zsuzsa Beke                                                                            +36 20 916 4507